Nektar Therapeutics Reports Financial Results for the Third Quarter of 2016
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- S&P 500, Dow set for higher open with focus on Mideast developments
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Don’t expect a grand bargain from the Trump-Xi summit: Yardeni
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Jefferies Raises Price Target on Nektar Therapeutics (NKTR) to $15
November 7, 2016 8:58 AM ESTJefferies reiterated a Buy on Nektar Therapeutics (NASDAQ: NKTR), and raised the price target to $15.00 (from $14.00), following the company's 3Q earnings report. Based on the recently completed equity offering and mgts updated guidance, Jefferies now estimates FY16 & FY17 revenues and EPS of $170M & ($1.17) and $284 & ($0.57) vs $188M &... More
Nektar Therapeutics (NKTR) Tops Q3 EPS by 4c
November 3, 2016 4:47 PM EDTNektar Therapeutics (NASDAQ: NKTR) reported Q3 EPS of ($0.32), $0.04 better than the analyst estimate of ($0.36). Revenue for the quarter came in at $36.3 million versus the consensus estimate of $32.42 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
... More